KALA BIO, Inc. entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell 2,928 Series F Convertible Non-Redeemable Preferred Stock at an issue price of $683 per preferred share for gross proceeds of $1,999,824 on December 21, 2023. The transaction is expected to close on December 22, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | +1.94% | -4.40% | -10.00% |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
Mar. 29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.00% | 17.74M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding